From Ahmedabad to Basel: How Indian Chemistry Powers Swiss Pharma's Global Engine

Switzerland processes $232.5 million in specialty chemical compounds from India annually, then re-exports precision-manufactured pharmaceuticals worth billions to markets across the EU, Americas, and Asia. This is not simple commodity trade. It is a globalised value chain where Indian intermediate compounds—amino-phenols, aromatic amines, and complex chemical precursors—flow into Swiss laboratories, emerge as finished medicines and APIs, and disperse worldwide. The architecture reveals mutual dependency between two precision manufacturing economies separated by 6,000 kilometres but unified by chemical necessity.

India's pharmaceutical exports reached USD 30.47 billion in 2024–25, registering a growth of 9.4 percent over the previous year, according to India's Commerce Ministry. Within that total, specialty chemical intermediates represent a crucial input—the building blocks that Swiss manufacturers import, refine, and package for global consumption. Switzerland's pharmaceutical exports totalled US$109.04 billion during 2024, making the country the world's largest per-capita pharma exporter. That dominance depends on feedstock arriving from India's chemical clusters.

The Chemistry Pipeline: From Andhra Pradesh and Gujarat to Swiss Formulation

The supply flow begins in three Indian pharmaceutical clusters. Hyderabad's industrial park named 'Hyderabad Pharma City' employs more than 560,000 industry professionals, with specialisation in active pharmaceutical ingredients and specialty compounds. The Ahmedabad pharma cluster hosts over 100 bulk drug producers and nearly 400 manufacturing units spanning allopathic and ayurvedic formulations, excipients, and specialised products. Many companies based in Mumbai are leaders in producing generic medicines, active pharmaceutical ingredients (APIs), and complex formulations, catering to domestic and international markets, and the city plays a crucial role in India's position as a global supplier of generic medicines and APIs.

From these hubs, intermediate compounds travel to Swiss contract manufacturers and pharmaceutical companies. The Swiss pharma manufacturing sector comprises approximately 48,000 employees across ~1,200 companies. The industry is dominated by major players: Roche, Novartis, Debiopharm and Lonza in the pharmaceuticals sector—giants that source precursor chemicals globally and re-export finished goods with Swiss brand and regulatory assurance.

The value chain operates bidirectionally. Swiss companies import speciality chemical compounds for processing, reformulation, and combination with proprietary molecular innovations. Approximately 95% of Swiss pharma manufacturing output is exported, primarily to the EU, US, and Asia. India supplies the foundation; Switzerland applies precision, R&D, and scale.

TEPA Accelerates Bilateral Dependency

The India-European Free Trade Association (EFTA) Agreement, signed on March 10 2024, aims to boost pharmaceutical exports to Switzerland, Iceland, Norway, and Liechtenstein. Under the TEPA, EFTA has opened 92.2% of tariff lines—encompassing 99.6% of India's exports—including 100% elimination of duties on non-agricultural products. That duty elimination applies directly to India's pharmaceutical intermediates, making Swiss sourcing cost-competitive relative to alternatives.

"The India-EFTA trade partnership represents a structural shift in pharmaceutical supply chain geography. Swiss companies now have tariff-free access to India's lowest-cost specialty chemistry, directly strengthening margins."

Cumulative Swiss FDI in India reached USD 9.95 billion between 2000 and 2023, concentrated in pharmaceuticals, financial services, machinery, and sustainable technologies. The TEPA framework is expected to accelerate this flow. EFTA has committed to channel USD 100 billion in FDI into India over 15 years, with the first USD 50 billion targeted within the initial decade, and the agreement also aims to generate one million direct jobs in India from these investment inflows.

Employment and Livelihoods: Factories Beyond Balance Sheets

The $232.5 million pharmaceutical supply chain feeding Switzerland translates into concrete employment across Indian states. Hyderabad's Pharma City employs more than 560,000 industry professionals, representing the world's single largest pharma employment cluster. Ahmedabad, Mumbai, and surrounding industrial towns host thousands of manufacturing facilities producing the intermediate compounds that Swiss companies purchase.

Using standard pharmaceutical sector employment multipliers—direct manufacturing jobs and indirect employment in logistics, quality assurance, and supply chain management—this trade flow supports an estimated 8,000-12,000 direct jobs in Indian pharmaceutical production dedicated to specialty chemical export manufacturing, plus another 18,000-22,000 indirect jobs in transportation, warehousing, and testing. Women comprise approximately 30% of the pharmaceutical manufacturing workforce, reflecting sector-wide patterns.

Strong linkages between SMEs, industrial associations, financial institutions, and research bodies have created a cohesive ecosystem in Ahmedabad. Similar networks exist in Hyderabad and Mumbai. These clusters function as employment ecosystems, not isolated factories. A single order from a Swiss CDMO (contract development and manufacturing organisation) cascades employment across 50-100 small and medium suppliers in chemical synthesis, quality testing, and logistics.

Most of these suppliers are MSMEs—enterprises with 10-500 employees, often family-managed and serving as the supply backbone. India supplies about 20% of the world's generic medicines and ranks third globally in drug production by volume, with over 60,000 generic brands made across more than 10,500 manufacturing sites. Each site represents wages, apprenticeships, and community anchor employment in towns like Vadodara, Ahmedabad, Hyderabad, and districts across Telangana and Gujarat.

Global Endpoints: Where Swiss-Processed Indian Inputs Reach Markets

The vast majority of chemical and pharmaceutical products are exported to the EU. Swiss manufacturers, having imported Indian intermediates, combine them with European innovation and export finished goods back to European healthcare systems, North American hospitals, and Asian markets. Germany, Italy, and Switzerland lead the world's pharmaceutical exporting countries by dollar value, driven by high-priced biologics and patented drugs, while India holds its own further down the list on the strength of volume and affordable generics. India provides volume inputs; Switzerland amplifies value and reach.

The reexport component matters strategically. Swiss customs data shows India-supplied intermediates re-enter global commerce as Swiss pharmaceutical products. That transformation—from Indian commodity to Swiss premium product—demonstrates value addition. Switzerland contributes intellectual property, regulatory compliance, brand assurance, and distribution networks. India contributes cost-effective synthesis and manufacturing at scale.

Forward Outlook: TEPA as Structural Enabler

March 2025 marked a high point, with exports reaching $3.68 billion—a 31.21% year-on-year growth compared to March 2024's $2.80 billion, highlighting the rising demand of India's pharmaceutical generics and the sector's growing competitiveness. That momentum extends into the Switzerland corridor. With tariff elimination under TEPA now in effect, cost pressures ease. Swiss manufacturers face no duty barriers on Indian imports. The value chain tightens, delivery times compress, and margin pressure on Swiss importers eases.

The Hyderabad Pharma City expansion, the Ahmedabad-Vadodara corridor's maturation, and Mumbai's continued dominance in API production ensure supply continuity. Indian pharmaceutical employment in these clusters will sustain and expand as Swiss demand stabilises under TEPA's preferential framework.

This is a story of complementary manufacturing economies linked by chemistry and tariff architecture. India makes the compounds efficiently; Switzerland processes them into medicines and reaches the world. Employment, innovation, and market access flow across borders, benefiting workers, companies, and patients in both nations.